Spots Global Cancer Trial Database for locally advanced hepatocellular carcinoma
Every month we try and update this database with for locally advanced hepatocellular carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | NCT04605731 | BCLC Stage B He... BCLC Stage C He... Locally Advance... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Durvalumab Tremelimumab | 18 Years - | City of Hope Medical Center | |
| Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | NCT03299946 | Locally Advance... | Cabozantinib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | NCT06066138 | Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela... | Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | NCT03299946 | Locally Advance... | Cabozantinib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | NCT03299946 | Locally Advance... | Cabozantinib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | NCT06066138 | Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela... | Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | NCT05199285 | BCLC Stage B He... BCLC Stage C He... Locally Advance... Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Ipilimumab Nivolumab | 18 Years - | Academic and Community Cancer Research United | |
| RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC | NCT05733598 | Locally Advance... Recurrent Hepat... Metastatic Hepa... | RP3 atezolizumab bevacizumab | 18 Years - | Replimune Inc. | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | NCT06066138 | Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela... | Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
